Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a Post-Market Evaluation of the Zephyr Valve 5.5-LP EBV to assess Treated Lobar Volume Reduction (TLVR), changes in lung function and the safety profile of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.
This is a multi-center, single-arm, prospective, observational study. Approximately 70 study participants undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV will be enrolled and followed out to 3 months. Assessments will be conducted at 45 days and 3 months. The evaluation will be conducted at up to 6 sites.
Patients prescribed Zephyr Valve treatment for their emphysema will be consented and will be enrolled only after: 1) determination of little to no collateral ventilation between target and ipsilateral lobes and 2) implantation of at least one Zephyr Valve 5.5-LP EBV. Baseline data will be collected retrospectively after enrollment of a patient in the Post-Market Evaluation. Performance and safety of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP will be evaluated post-treatment based on data collected until 3 months after the treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment | Patients undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP | Device | The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks. |
| Measure | Description | Time Frame |
|---|---|---|
| Treated Lobar Volume Reduction (TLVR) responders | The percentage of patients treated with the Zephyr Valve 5.5-LP EBV who achieved a Treated Lobar Volume Reduction (TLVR) of the treated lobe (s) of ≥350ml as seen via HRCT at 45-days. | 45 days |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Treated Lobar Volume Reduction (TLVR) changes from Baseline | Treated Lobar Volume Reduction (TLVR) as seen via HRCT at 45-days (absolute and percent changes from baseline). | 45 days |
| Lobar occlusion | Lobar occlusion of the treated lobe at 45-days post-procedure as visualized by HRCT. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The population evaluated will comprise of patients with hyperinflation associated with severe emphysema that are considered appropriate for the procedure by their physician, confirmed to have little to no collateral ventilation and had at least one Zephyr Valve 5.5-LP EBV implanted during the procedure.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ruhrlandklinik Essen - Universitätsmedizin | Essen | 45239 | Germany | |||
| University Hospital of Zurich |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011656 | Pulmonary Emphysema |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 45 days |
| Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1) | Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1) at 3-months (absolute and percent changes from baseline). | 3 months |
| Residual Volume (RV) | Residual Volume at 3 months, when available (absolute and percent changes from baseline). | 3 months |
| Total Lung Capacity | Total Lung Capacity (TLC) at 3 months, when available (absolute and percent changes from baseline). | 3 months |
| Inspiratory Capacity | Inspiratory Capacity (IC) at 3 months, when available (absolute and percent changes from baseline). | 3 months |
| Residual Volume/Total Lung Capacity (RV/TLC) | RV/TLC ratio at 3 months, when available (absolute and percent changes from baseline). | 3 months |
| Inspiratory Capacity/Total Lung Capacity (IC/TLC) | IC/TLC ratio at 3 months, when available (absolute and percent changes from baseline). | 3 months |
| Zurich |
| 8091 |
| Switzerland |
| Royal Brompton Hospital | London | SW3 6NP | United Kingdom |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |